{"doi":"10.1159/000446438","title":"Smoking History as a Predictor of Pemetrexed Monotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer","abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; Pemetrexed monotherapy has come to be recognized as the standard of care for second-line therapy of non-squamous non-small cell lung cancer (NSCLC). Thymidylate synthase (TS) expression is recognized as a potential predictor of the response to pemetrexed-based chemotherapy in patients with advanced NSCLC. The purpose of this study was to identify useful predictors of the response to pemetrexed other than TS expression. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; The records of non-squamous NSCLC patients without driver mutations who received pemetrexed monotherapy as a second or later line of chemotherapy at Kitasato University Hospital between March 2009 and October 2015 were retrospectively reviewed, and the treatment outcomes were evaluated. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; In the 116 patients with non-squamous NSCLC, the overall response rate and progression-free survival (PFS) were 10.3% and 2.1 months, respectively. The disease control rate and PFS differed significantly among current smokers and never-smokers/former light smokers (44.9 vs. 65.8%, and 1.8 vs. 4.0 months, respectively). Furthermore, multivariate analysis identified Eastern Cooperative Oncology Group Performance Status and smoking status as independent predictors of the PFS. &lt;b&gt;&lt;i&gt;Conclusion:&lt;/i&gt;&lt;/b&gt; The clinical data obtained in this study may provide a valuable basis for the use of smoking status as a predictor of pemetrexed monotherapy in wild-type NSCLC patients.</jats:p>","journal":"Oncology","year":2016,"id":18957,"datarank":0.9128091184721896,"base_score":2.302585092994046,"endowment":2.302585092994046,"self_citation_contribution":0.3453877639491069,"citation_network_contribution":0.5674213545230826,"self_endowment_contribution":0.3453877639491069,"citer_contribution":0.5674213545230826,"corpus_percentile":null,"corpus_rank":null,"citation_count":9,"citer_count":8,"citers_with_citation_signal":8,"citers_with_endowment":8,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":129914,"name":"Jiichiro Sasaki","orcid":null,"position":1,"is_corresponding":false},{"id":129915,"name":"Sakiko Otani","orcid":null,"position":2,"is_corresponding":false},{"id":129916,"name":"Masayuki Shirasawa","orcid":null,"position":3,"is_corresponding":false},{"id":129917,"name":"Hideyuki Niwa","orcid":null,"position":4,"is_corresponding":false},{"id":129918,"name":"Seiichiro Kusuhara","orcid":null,"position":5,"is_corresponding":false},{"id":129919,"name":"Shinya Harada","orcid":null,"position":6,"is_corresponding":false},{"id":129920,"name":"Masaru Kubota","orcid":null,"position":7,"is_corresponding":false},{"id":129921,"name":"Masato Katagiri","orcid":null,"position":8,"is_corresponding":false},{"id":129922,"name":"Noriyuki Masuda","orcid":null,"position":9,"is_corresponding":false},{"id":129913,"name":"Satoshi Igawa","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":2.302585092994046,"endowment":2.302585092994046,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"27234033","pmcid":null,"openalex_id":"https://openalex.org/W2400780793","authors":[],"funders":[],"total_grants":0,"fwci":1.5423,"citation_percentile":0.83751146,"influential_citations":0,"citation_trend":[{"year":2016,"count":1},{"year":2018,"count":4},{"year":2019,"count":1},{"year":2020,"count":2},{"year":2023,"count":1}],"oa_status":"closed","license":"https://www.karger.com/Services/SiteLicenses","oa_locations":[{"url":"https://www.karger.com/Article/Pdf/446438","host_type":"publisher"},{"url":"https://doi.org/10.1159/000446438","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/27234033","host_type":"repository"}],"fields_of_study":["Lung Cancer Treatments and Mutations","Lung Cancer Diagnosis and Treatment","Lung Cancer Research Studies","Medicine","Adult","Aged","Aged, 80 and over","Antineoplastic Agents","Carcinoma, Non-Small-Cell Lung","Cohort Studies","Disease-Free Survival","Enzyme Inhibitors","Female","Humans","Infusions, Intravenous","Lung Neoplasms","Male","Middle Aged","Pemetrexed","Retrospective Studies","Smoking"],"mesh_terms":["Pemetrexed","Adult","Aged","Aged, 80 and over","Antineoplastic Agents","Carcinoma, Non-Small-Cell Lung","Enzyme Inhibitors","Female","Humans","Infusions, Intravenous","Lung Neoplasms","Male","Middle Aged","Retrospective Studies","Smoking","Cohort Studies","Disease-Free Survival"],"keywords":["Pemetrexed","Thymidylate synthase","Medicine","Oncology","Internal medicine","Lung cancer","Chemotherapy","Performance status","Multivariate analysis","Cisplatin","Fluorouracil"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-04T00:47:33.802900Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}